CompanyGraph
Sells both branded and generic versions of the same drugs — like Lipitor and Lyrica — across 165 markets.
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleRevenue is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: distress zone
- Interpretations1 currently firing — 1
What this company is and how it runs — written from structure, not news.
Viatris sells both the branded versions of drugs like Lipitor, Lyrica, and Norvasc and the generic versions of the same molecules across 165 markets, using the branded revenue to pay the costs of waiting out the 12-to-48-month FDA approval process that every new generic filing requires. Because that approval window is set by agency review and clinical study timelines rather than by how much money a company spends, a generic-only manufacturer filing the same molecules has to borrow external capital to cover the gap — Viatris covers it from its own income statement. This lets Viatris absorb the aggressive pricing that comes with being first to market on a generic without destroying its margins, which a competitor without a branded leg on the same drug cannot do as easily. The structure depends entirely on those branded revenues holding up: if a patent challenge, compulsory licensing action, or regulatory ruling strips the branded cash flow from Lipitor or Lyrica in a major market, the internal funding mechanism disappears and the generic pipeline stalls at exactly the moment it was supposed to pay off.
How does this company make money?
The company charges wholesalers a per-unit price for both branded products — like Lipitor and Norvasc — and generic versions of the same drugs. The most valuable revenue comes in during the period right after a generic is first approved, when Viatris may be the only generic seller and can charge higher prices before other competitors enter and drive prices down.
What makes this company hard to replace?
The bioequivalence data Viatris has already filed with the FDA for its existing products took years and significant clinical work to generate — a competitor must run its own independent studies from scratch to match it. Pharmacy benefit managers have locked in formulary placements through existing pricing contracts, which take time and renegotiation to change. New manufacturing entrants also have to build their own inspection history with regulatory agencies, a track record that Viatris's facilities already carry.
What limits this company?
Every new generic filing requires its own clinical studies and a separate regulatory review in each country, and that process takes 12 to 48 months no matter how much money or manufacturing capacity the company adds. Building more factories or hiring more staff does not shorten the line — the bottleneck is the agency review clock itself.
What does this company depend on?
The company cannot operate without active pharmaceutical ingredient suppliers who provide the atorvastatin used in Lipitor and the pregabalin used in Lyrica. It also depends on maintaining FDA manufacturing facility registrations across its production sites, bioequivalence testing laboratories that generate the clinical data required for each ANDA submission, and Good Manufacturing Practice certifications for every facility. It also needs continuous patent litigation monitoring to know when exclusivity windows on target molecules are open.
Who depends on this company?
Pharmacy benefit managers rely on Viatris generics to offer cheaper alternatives that reduce drug costs for the populations they cover — if those generics disappeared, formulary costs would rise. Hospital systems depend on affordable versions of cardiovascular and neurological medicines for everyday patient care; losing access would pressure their drug budgets. Medicare Part D plans count on generic substitution for high-volume prescriptions to keep their own economics viable.
How does this company scale?
As production volumes grow, the fixed costs of manufacturing setup and regulatory filing are spread across more doses, so the cost per pill falls. What does not get cheaper with scale is the approval process itself — each new generic still requires its own clinical studies and its own country-by-country review, and those cannot be batched or accelerated by producing more pills.
What external forces can significantly affect this company?
Patent cliffs — the dates when major branded drugs lose exclusivity — create market entry windows that competitors can anticipate and plan around, independent of anything Viatris does. Currency swings affect what the company pays to international chemical suppliers for active ingredients like atorvastatin and pregabalin. Medicare negotiation policies can compress reimbursement rates for generic drugs across every manufacturer at once, squeezing margins industry-wide.
Where is this company structurally vulnerable?
If a court ruled against Viatris in a patent case, or if a government forced compulsory licensing, or if a regulator revoked market exclusivity on Lipitor, Lyrica, or Norvasc in a major country, the branded revenue that pays for the generic approval waiting period would shrink or disappear. Without that income cushion, the company could no longer absorb the cost of pending generic filings the way it currently does, and its pipeline would stall.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Up-Close-Week Share With Multi-Year Net-Income and Gross-Profit Decrease
A high share of weekly closes over the trailing year were higher than the prior week; net income decreased across the last 4 year-over-year transitions; gross profit also decreased across the last 4 year-over-year transitions.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.